Skip to main content
SpringerLink
Log in

New discoveries in the basic science understanding of Peyronie’s disease

  • Published:
Current Urology Reports Aims and scope Submit manuscript

Abstract

Peyronie’s disease is an acquired benign condition representing localized fibrosis of the penis. The disease is caused by microvascular trauma to the penis, with subsequent fibrin deposition resulting in aberrant wound healing and possibly other etiologies. Histopathologic studies of the Peyronie’s plaque have demonstrated the role of transforming growth factor-â1 in the pathologic development of penile plaque. Animal models have been developed to test pathophysiology and therapeutics. The role of inducible nitric oxide synthase and nitric oxide has been established to limit and counteract fibrosis. Differential gene expression studies have identified candidate up-regulated or down-regulated genes that are involved in the pathophysiology of Peyronie’s disease

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. de La Peyronie F: Sur Quelsques obstacles qui s’opposent a l’ejaculation naturelle de la semance. Med Aca R Chir 1743, 1:425.

    Google Scholar 

  2. Lindsay MB, Schain DM, Grambsch P, et al.: The incidence of Peyronie’s disease in Rochester, Minnesota, 1950 through 1984. J Urol 1991, 146:1007–1009.

    PubMed  CAS  Google Scholar 

  3. Schwarzer U, Sommer F, Klotz T, et al.: The prevalence of Peyronie’s disease: results of a large survey. BJU Int 2001, 88:727–730.

    Article  PubMed  CAS  Google Scholar 

  4. Mulhall JP, Creech SD, Boorjian SA, et al.: Subjective and objective analysis of the prevalence of Peyronie’s disease in a population of men presenting for prostate cancer screening. J Urol 2004, 171:2350–2353.

    Article  PubMed  Google Scholar 

  5. Kadioglu A, Oktar T, Kandirali E, et al.: Incidentally diagnosed Peyronie’s disease in men presenting with erectile dysfunction. Int J Impot Res 2004 [Epub head of print].

  6. Williams JL, Thomas GG: The natural history of Peyronie’s disease. J Urol 1970, 103:75–76.

    PubMed  CAS  Google Scholar 

  7. Gelbard MK, Dorey F, James K: The natural history of Peyronie’s disease. J Urol 1990, 144:1376–1379.

    PubMed  CAS  Google Scholar 

  8. Smith BH: Peyronie’s disease. Am J Clin Pathol 1966, 45:670–678.

    PubMed  CAS  Google Scholar 

  9. Somers KD, Dawson DM: Fibrin deposition in Peyronie’s disease plaque. J Urol 1997, 157:311–315.

    Article  PubMed  CAS  Google Scholar 

  10. Furey CA: Peyronie’s disease: a treatment by the local injection of meticortelone and hydrocortisone. J Urol 1957, 55:251–266.

    Google Scholar 

  11. Jarow JP, Lowe FC: Penile trauma: an etiologic factor in Peyronie’s disease and erectile dysfunction. J Urol 1997, 158:1388–1390.

    Article  PubMed  CAS  Google Scholar 

  12. Devine CJ Jr, Somers KD, Jordan SG, Schlossberg SM: Proposal: trauma as the cause of the Peyronie’s lesion. J Urol 1997, 157:285–290.

    Article  PubMed  Google Scholar 

  13. Brock G, Hsu GL, Nunes L, et al.: The anatomy of the tunica albuginea in the normal penis and Peyronie’s disease. J Urol 1997, 157:276–281.

    Article  PubMed  CAS  Google Scholar 

  14. Bystrom J, Rubio C: Induratio penis plastica Peyronie’s disease: clinical features and etiology. Scand J Urol Nephrol 1976, 10:12–20.

    PubMed  CAS  Google Scholar 

  15. Ling RS: The genetic factor in Dupuytren’s disease. J Bone Joint Surg 1963, 45:709–718.

    CAS  Google Scholar 

  16. Chilton CP, Castle WM, Westwood CA, Pryor JP: Factors associated in the aetiology of Peyronie’s disease. Br J Urol 1982, 54:748–750.

    PubMed  CAS  Google Scholar 

  17. Nyberg LM Jr, Bias WB, Hochberg MC, Walsh PC: Identification of an inherited form of Peyronie’s disease with autosomal dominant inheritance and association with Dupuytren’s contracture and histocompatibility B7 cross-reacting antigens. J Urol 1982, 128:48–51.

    PubMed  Google Scholar 

  18. Willscher MK, Cwazka WF, Novicki DE: The association of histocompatibility antigens of the B7 cross-reacting group with Peyronie’s disease. J Urol 1979, 122:34–35.

    PubMed  CAS  Google Scholar 

  19. Ziegelbaum M, Thomas A Jr, Zachary AA: The association of Peyronie’s disease with HLA B7 cross-reactive antigens: a case report of identical twins. Cleve Clin J Med 1987, 54:427–430.

    PubMed  CAS  Google Scholar 

  20. Rompel R, Mueller-Eckhardt G, Schroeder-Printzen I, Weidner W: HLA antigens in Peyronie’s disease. Urol Int 1994, 52:34–37.

    Article  PubMed  CAS  Google Scholar 

  21. Rompel R, Weidner W, Mueller-Eckhardt G: HLA association of idiopathic Peyronie’s disease: an indication of autoimmune phenomena in etiopathogenesis? Tissue Antigens 1991, 38:104–106.

    PubMed  CAS  Google Scholar 

  22. Hauck EW, Hauptmann A, Weidner W, et al.: Prospective analysis of HLA classes I and II antigen frequency in patients with Peyronie’s disease. J Urol 2003, 170:1443–1446.

    Article  PubMed  CAS  Google Scholar 

  23. Schiavino D, Sasso F, Nucera E, et al.: Immunologic findings in Peyronie’s disease: a controlled study. Urology 1997, 50:764–768.

    Article  PubMed  CAS  Google Scholar 

  24. Ralph DJ, Schwartz G, Moore W, et al.: The genetic and bacteriological aspects of Peyronie’s disease. J Urol 1997, 157:291–294.

    Article  PubMed  CAS  Google Scholar 

  25. Hauck EW, Domann E, Hauptmann A, et al.: Prospective analysis of 16S rDNA as a highly sensitive marker for bacterial presence in Peyronie’s disease plaques. J Urol 2003, 170:2053–2056.

    Article  PubMed  CAS  Google Scholar 

  26. El-Sakka AI, Hassoba HM, Pillarisetty RJ, et al.: Peyronie’s disease is associated with an increase in transforming growth factor-beta protein expression. J Urol 1997, 158:1391–1394.

    Article  PubMed  CAS  Google Scholar 

  27. Border WA, Ruoslahti E: Transforming growth factor-beta in disease: the dark side of tissue repair. J Clin Invest 1992, 90:1–7.

    Article  PubMed  CAS  Google Scholar 

  28. Shah M, Foreman DM, Ferguson MW: Control of scarring in adult wounds by neutralising antibody to transforming growth factor beta. Lancet 1992, 339:213–214.

    Article  PubMed  CAS  Google Scholar 

  29. El-Sakka AI, Selph CA, Yen TS, et al.: The effect of surgical trauma on rat tunica albuginea. J Urol 1998, 159:1700–1707.

    Article  PubMed  CAS  Google Scholar 

  30. El-Sakka AI, Hassoba HM, Chui RM, et al.: An animal model of Peyronie’s-like condition associated with an increase of transforming growth factor beta mRNA and protein expression. J Urol 1997, 158:2284–2290.

    Article  PubMed  CAS  Google Scholar 

  31. Bivalacqua TJ, Diner EK, Novak TE, et al.: A rat model of Peyronie’s disease associated with a decrease in erectile activity and an increase in inducible nitric oxide synthase protein expression. J Urol 2000, 163:1992–1998.

    Article  PubMed  CAS  Google Scholar 

  32. Bivalacqua TJ, Champion HC, Leungwattanakij S, et al.: Evaluation of nitric oxide synthase and arginase in the induction of a Peyronie’s-like condition in the rat. J Androl 2001, 22:497–506.

    PubMed  CAS  Google Scholar 

  33. Davila HH, Ferrini MG, Rajfer J, Gonzalez-Cadavid NF: Fibrin as an inducer of fibrosis in the tunica albuginea of the rat: a new animal model of Peyronie’s disease. BJU Int 2003, 91:830–838.

    Article  PubMed  CAS  Google Scholar 

  34. Chung SI, Lee SY, Uchino R, Carmassi F: Factors that control extravascular fibrinolysis. Semin Thromb Hemost 1996, 22:479–488.

    Article  PubMed  CAS  Google Scholar 

  35. Lue TF: Peyronie’s disease: an anatomically based hypothesis and beyond. Int J Impot Res 2002, 14:411–413.

    Article  PubMed  CAS  Google Scholar 

  36. Lin CS, Lin G, Wang Z, et al.: Upregulation of monocyte chemoattractant protein 1 and effects of transforming growth factor-beta 1 in Peyronie’s disease. Biochem Biophys Res Commun 2002, 295:1014–1019.

    Article  PubMed  CAS  Google Scholar 

  37. Wang Z, Lin G, Lue TF, Lin CS: Wogonin suppresses cellular proliferation and expression of monocyte chemoattractant protein 1 in Peyronie’s plaque-derived cells. BJU Int 2003, 92:753–757.

    Article  PubMed  CAS  Google Scholar 

  38. Gentile V, Modesti A, La Pera G, et al.: Ultrastructural and immunohistochemical characterization of the tunica albuginea in Peyronie’s disease and veno-occlusive dysfunction. J Androl 1996, 17:96–103.

    PubMed  CAS  Google Scholar 

  39. Wahl SM: Inflammation and growth factors. J Urol 1997, 157:303–305.

    Article  PubMed  CAS  Google Scholar 

  40. Somers KD, Dawson DM, Wright GL Jr, et al.: Cell culture of Peyronie’s disease plaque and normal penile tissue. J Urol 1982, 127:585–588.

    PubMed  CAS  Google Scholar 

  41. Somers KD, Winters BA, Dawson DM, et al.: Chromosome abnormalities in Peyronie’s disease. J Urol 1987, 137:672–675.

    PubMed  CAS  Google Scholar 

  42. Mulhall JP, Nicholson B, Pierpaoli S, et al.: Chromosomal instability is demonstrated by fibroblasts derived from the tunica of men with Peyronie’s disease. Int J Impot Res 2004, 16:288–293.

    Article  PubMed  CAS  Google Scholar 

  43. Perinchery G, El-Sakka AI, Angan A, et al.: Microsatellite alterations and loss of heterozygosity in Peyronie’s disease. J Urol 2000, 164:842–846.

    Article  PubMed  CAS  Google Scholar 

  44. Ferrini MG, Vernet D, Magee TR, et al.: Antifibrotic role of inducible nitric oxide synthase. Nitric Oxide 2002, 6:283–294.

    Article  PubMed  CAS  Google Scholar 

  45. Vernet D, Ferrini MG, Valente EG, et al.: Effect of nitric oxide on the differentiation of fibroblasts into myofibroblasts in the Peyronie’s fibrotic plaque and in its rat model. Nitric Oxide 2002, 7:262–276.

    Article  PubMed  CAS  Google Scholar 

  46. Mulhall JP: Expanding the paradigm for plaque development in Peyronie’s disease. Int J Impot Res 2003, 15(suppl 5):S93-S102. Critical study.

    Article  PubMed  Google Scholar 

  47. Valente EG, Vernet D, Ferrini MG, et al.: L-arginine and phosphodiesterase (PDE) inhibitors counteract fibrosis in the Peyronie’s fibrotic plaque and related fibroblast cultures. Nitric Oxide 2003, 9:229–244.

    Article  PubMed  CAS  Google Scholar 

  48. Davila HH, Magee TR, Vernet D, et al.: Gene transfer of inducible nitric oxide synthase complementary DNA regresses the fibriotic plaque in an animal model of Peyronie’s disease. Biol Reprod 2004, 71:1568–1577.

    Article  PubMed  CAS  Google Scholar 

  49. Magee TR, Qian A, Rajfer J, et al.: Gene expression profiles in the Peyronie’s disease plaque. Urology 2002, 59:451–457.

    Article  PubMed  Google Scholar 

  50. Kolb M, Margetts PJ, Galt T, et al.: Transient transgene expression of decorin in the lung reduces the fibrotic response to bleomycin. Am J Respir Crit Care Med 2001, 163:770–777.

    PubMed  CAS  Google Scholar 

  51. Qian A, Meals RA, Rajfer J, Gonzalez-Cadavid NF: Comparison of gene expression profiles between Peyronie’s disease and Dupuytren’s contracture. Urology 2004, 64:399–404. Interesting study.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Urology, University of California at Los Angeles, School of Medicine, Division of Urology, Research and Education Institute, Harbor-UCLA Medical Center, 1000 W. Carson Street, Box 5, 90509, Torrance, CA, USA

    Jacob Rajfer MD

Authors
  1. Mark Jalkut MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Nestor Gonzalez-Cadavid MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Jacob Rajfer MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Jalkut, M., Gonzalez-Cadavid, N. & Rajfer, J. New discoveries in the basic science understanding of Peyronie’s disease. Curr Urol Rep 5, 478–484 (2004). https://doi.org/10.1007/s11934-004-0074-y

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11934-004-0074-y

Keywords

Search

Navigation